Open access
Open access
Powered by Google Translator Translator

RCT | Long-term survival benefit with abiraterone plus ADT in metastatic PC, but no advantage with enzalutamide association

8 May, 2023 | 13:02h | UTC

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol – The Lancet Oncology


Commentary on Twitter


Stay Updated in Your Specialty

Telegram Channels

WhatsApp alerts 10-day free trial

No spam, just news.